EXAS - EXACT Sciences - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30063P1057

Cancer, Diagnostic, Screening, Tests, DNA, Colorectal, Oncology

Exact Sciences Corporation is a pioneering biotech company that specializes in developing innovative cancer screening and diagnostic tests. With a strong focus on early detection and prevention, the company offers a range of products that help identify cancer biomarkers and genetic mutations.

One of its flagship products is Cologuard, a non-invasive, stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. This test has revolutionized the way colorectal cancer is detected, providing a convenient and accurate way to identify potential issues.

In addition to Cologuard, Exact Sciences offers a suite of other diagnostic tests, including the Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, and Oncotype DX Colon Recurrence Score Test. These tests provide valuable insights into the genetic makeup of tumors, helping doctors develop personalized treatment plans for their patients.

The company is also at the forefront of tumor profiling, with its OncoExTra Test, which helps identify genetic mutations in patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. Furthermore, Exact Sciences has expanded its services to include Covid-19 testing, providing critical support during the pandemic.

Exact Sciences has a robust pipeline of products in development, focused on enhancing the performance characteristics of Cologuard and creating new blood and fluid-based tests. The company has established strategic partnerships with renowned institutions like the MAYO Foundation for Medical Education and Research and Johns Hopkins University, further solidifying its position as a leader in the field of cancer diagnostics.

With a rich history dating back to 1995, Exact Sciences Corporation is headquartered in Madison, Wisconsin, and continues to drive innovation in cancer diagnostics and treatment. To learn more about the company and its groundbreaking work, visit their website at https://www.exactsciences.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for EXAS - EXACT Sciences  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for EXAS - EXACT Sciences  - Stock Price & Dividends

EXAS Stock Overview

Market Cap in USD 8,555m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2001-02-01

EXAS Stock Ratings

Growth 5y -53.5
Fundamental -23.0
Dividend 0.00
Rel. Performance vs Sector -4.24
Analysts 4.65/5
Fair Price Momentum 37.44 USD
Fair Price DCF 4.56 USD

EXAS Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

EXAS Growth Ratios

Growth 12m -50.74%
Growth Correlation 12m -64%
Growth Correlation 3m -52%
CAGR 5y -16.57%
CAGR/Mean DD 5y -0.38
Sharpe Ratio 12m -1.18
Alpha vs SP500 12m -80.60
Beta vs SP500 5y weekly 1.38
ValueRay RSI 79.56
Volatility GJR Garch 1y 55.63%
Price / SMA 50 0.19%
Price / SMA 200 -22.16%
Current Volume 2398.1k
Average Volume 20d 3088.3k

External Links for EXAS Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of EXAS stocks?
As of July 21, 2024, the stock is trading at USD 46.81 with a total of 2,398,069 shares traded.
Over the past week, the price has changed by +0.97%, over one month by +6.39%, over three months by -23.21% and over the past year by -50.12%.
What are the forecast for EXAS stock price target?
According to ValueRays Forecast Model, EXAS EXACT Sciences will be worth about 41.3 in July 2025. The stock is currently trading at 46.81. This means that the stock has a potential downside of -11.71%.
Issuer Forecast Upside
Wallstreet Target Price 80.9 72.8
Analysts Target Price 106.4 127
ValueRay Target Price 41.3 -11.7